Orthofix International N.V. (NASDAQ:OFIX) posted its quarterly earnings data on Monday. The medical device company reported $0.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.04, Bloomberg Earnings reports. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. The business had revenue of $105.30 million for the quarter, compared to analysts’ expectations of $100.67 million. During the same quarter in the previous year, the firm earned $0.36 earnings per share. The business’s revenue was up 6.9% on a year-over-year basis. Orthofix International N.V. updated its FY17 guidance to $1.54-1.63 EPS.
Orthofix International N.V. (NASDAQ OFIX) opened at 49.85 on Tuesday. Orthofix International N.V. has a 12 month low of $32.51 and a 12 month high of $51.09. The stock’s 50 day moving average price is $48.89 and its 200-day moving average price is $45.55. The stock has a market cap of $905.77 million, a PE ratio of 116.74 and a beta of 0.20.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/10/30/orthofix-international-n-v-ofix-posts-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.
Several research firms have weighed in on OFIX. Jefferies Group LLC reissued a “buy” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Orthofix International N.V. in a research report on Thursday, August 10th. BidaskClub cut Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research raised Orthofix International N.V. from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research report on Thursday, August 10th. Finally, TheStreet raised Orthofix International N.V. from a “c+” rating to a “b-” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $52.75.
In other news, CFO Rice Doug sold 7,353 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the transaction, the chief financial officer now directly owns 44,743 shares in the company, valued at approximately $2,212,988.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Bradley V. Niemann sold 6,956 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $49.44, for a total value of $343,904.64. Following the completion of the transaction, the insider now owns 40,178 shares in the company, valued at $1,986,400.32. The disclosure for this sale can be found here. In the last three months, insiders sold 23,406 shares of company stock valued at $1,138,531. Corporate insiders own 5.60% of the company’s stock.
Orthofix International N.V. Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
What are top analysts saying about Orthofix International N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Orthofix International N.V. and related companies.